Skip to main content
. 2021 Nov 25;10(12):3301. doi: 10.3390/cells10123301

Figure 4.

Figure 4

Chip simulation assay. Anti-cancer drug was treated in the first well with or without an SI organoid in the second well. For the control, only Matrigel was placed instead of the SI organoid in the second well. The spheroids’ viability in the third well was measured to validate the working of the FPM chip. When Docetaxel was used to treat the SI organoid, there was no specific change of the spheroids’ viability in the third well, but the Docetaxel without the organoid significantly decreased the viability at 72 h. Scheme of the simulation assay (A), total cell number and metabolic activity assay using CellTiter Glo® 3D after 72 h flow in Docetaxel (B) and Paclitaxel (C). The differences were considered significant at p < 0.05 (*).